These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 15177539)

  • 1. Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab.
    Korzenik JR
    Gastroenterol Clin North Am; 2004 Jun; 33(2):285-301, ix. PubMed ID: 15177539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcending conventional therapies: the role of biologic and other novel therapies.
    Sandborn WJ
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-TNF agents in Crohn's disease.
    Van Assche G; Rutgeerts P
    Expert Opin Investig Drugs; 2000 Jan; 9(1):103-11. PubMed ID: 11060664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives.
    Blam ME; Stein RB; Lichtenstein GR
    Am J Gastroenterol; 2001 Jul; 96(7):1977-97. PubMed ID: 11467623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease.
    van Deventer SJ
    Gastroenterology; 2001 Nov; 121(5):1242-6. PubMed ID: 11677219
    [No Abstract]   [Full Text] [Related]  

  • 6. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.
    Van den Brande JM; Braat H; van den Brink GR; Versteeg HH; Bauer CA; Hoedemaeker I; van Montfrans C; Hommes DW; Peppelenbosch MP; van Deventer SJ
    Gastroenterology; 2003 Jun; 124(7):1774-85. PubMed ID: 12806611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies targeting tumor necrosis factor in Crohn's disease.
    Sandborn WJ
    Acta Gastroenterol Belg; 2001; 64(2):170-2. PubMed ID: 11475128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease.
    Akobeng AK; Zachos M
    Cochrane Database Syst Rev; 2004; 2003(1):CD003574. PubMed ID: 14974022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease.
    Sandborn WJ
    Curr Gastroenterol Rep; 2003 Dec; 5(6):501-5. PubMed ID: 14602060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease.
    Sandborn WJ
    Rev Gastroenterol Disord; 2005; 5(1):10-8. PubMed ID: 15741928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF-alpha antagonists for the treatment of Crohn's disease.
    Kam LY; Targan SR
    Expert Opin Pharmacother; 2000 May; 1(4):615-22. PubMed ID: 11249506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why do anti-tumor necrosis factor antibodies work in Crohn's disease?
    Sands BE
    Rev Gastroenterol Disord; 2004; 4 Suppl 3():S10-7. PubMed ID: 15580148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases.
    LaDuca JR; Gaspari AA
    Dermatol Clin; 2001 Oct; 19(4):617-35. PubMed ID: 11705350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a role for tumor necrosis factor-alpha inhibitors and especially thalidomide in dermatology?
    Moschella SL
    Skinmed; 2005; 4(1):19-30; quiz 31-2. PubMed ID: 15654161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases.
    Kalden JR
    Arthritis Res; 2002; 4 Suppl 2(Suppl 2):S34-40. PubMed ID: 12110156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab induced T lymphocyte apoptosis in Crohn's disease.
    van den Brande J; Hommes DW; Peppelenbosch MP
    J Rheumatol Suppl; 2005 Mar; 74():26-30. PubMed ID: 15742461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases.
    Feldman M; Taylor P; Paleolog E; Brennan FM; Maini RN
    Transplant Proc; 1998 Dec; 30(8):4126-7. PubMed ID: 9865320
    [No Abstract]   [Full Text] [Related]  

  • 18. Patient outcomes after anti TNF-alpha drugs for Crohn's disease.
    Assasi N; Blackhouse G; Xie F; Marshall JK; Irvine EJ; Gaebel K; Robertson D; Campbell K; Hopkins R; Goeree R
    Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):163-75. PubMed ID: 20384563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease.
    Lichtenstein GR
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S23-9. PubMed ID: 11380040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.